Non-immunogenic staphylokinase in the treatment of high-risk massive pulmonary embolism in the early postoperative period due to femoral fragment wound

• Published in: Rat͡s︡ionalʹnai͡a︡ farmakoterapii͡a︡ v kardiologii Vol. 19; no. 5; pp. 495 - 501
• Main Authors: Konstantinov, S. L., Stryabkova, G. I., Basarab, A. I., Kravchuk, V. N., Kаzhanov, I. V., Ivanov, S. V., Chefranova, Zh. Yu, Markin, S. S.
• Format: Journal Article
• Language: English
• Published: Столичная издательская компания 07.11.2023
• Subjects: non-immunogenic staphylokinase; postoperative period; pulmonary embolism; risk of bleeding
• ISSN: 1819-6446; 2225-3653
• DOI: 10.20996/1819-6446-2023-2957

A case report of double thrombolytic therapy with non-immunogenic staphylokinase at a dose of 15 mg bolus over 15 s in a patient with a high-risk massive pulmonary embolism (PE) in the early postoperative period due to femoral wound is described. After the second thrombolysis, a decrease in the pulmonary arteries thrombotic lesions according to multislice computed tomography data, restoration of right ventricular function, and a decrease in pulmonary hypertension were observed. Reuse of the non-immunogenic staphylokinase did not lead to the major bleeding and hemorrhagic stroke, did not provoke a drop in hemoglobin and did not require blood transfusion. Upon discharge of the patient, normalization of the general blood test parameters was noted: the level of hemoglobin increased from 86 to 112 g/l, erythrocytes — from 2.8 to 3.5x1012/l, hematocrit — from 26 to 32%. Thus, non-immunogenic staphylokinase has demonstrated high efficacy and safety in the treatment of patient with a high-risk massive PE in the early postoperative period.